Ascendis Pharma A/S
Ascendis Pharma A/S works on 3 rare diseases tracked on Trial Friend, including Achondroplasia, Hypoparathyroidism, Turner Syndrome, with 10 active clinical trials (8 recruiting) and 3 FDA-approved rare disease drugs.
Ascendis Pharma is a biopharmaceutical company applying its TransCon technology platform to develop long-acting prodrug therapies for rare endocrine diseases. The company markets Skytrofa for pediatric growth hormone deficiency, Yorvipath for hypoparathyroidism, and Yuviwel for achondroplasia.
Focus areas at Ascendis Pharma A/S
As a rare disease specialist, Ascendis Pharma A/S has active clinical trial programs and drug development efforts across 3 rare diseases, including Achondroplasia, Hypoparathyroidism, Turner Syndrome. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by Ascendis Pharma A/S, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Ascendis Pharma A/S is headquartered in Copenhagen, Denmark, founded in 2007, publicly traded under the ticker symbol ASND. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Ascendis Pharma A/S Drug Pipeline
Ascendis Pharma A/S has 10 active clinical trials across 3 development stages, with 8 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline counts the active and recruiting trials listed on this page, from ClinicalTrials.gov. For companies that work outside rare disease, we list only trials for rare diseases we track, so the company's full pipeline may be larger.
Ascendis Pharma A/S Clinical Trials (10)
Active and recruiting clinical trials sponsored by Ascendis Pharma A/S, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
Ascendis Pharma A/S FDA-Approved Drugs (3)
Medications developed or marketed by Ascendis Pharma A/S that have received U.S. Food and Drug Administration approval. Drug data is sourced from the openFDA database and includes brand names, generic names, approval dates, and matched rare disease indications. Where a drug treats a condition covered by Trial Friend, the disease name links directly to that disease page.
| Drug Name | Brand Name | Rare Diseases | Approval Date |
|---|---|---|---|
| LONAPEGSOMATROPIN-TCGD Recombinant Human Growth Hormone [EPC] | Skytrofa subcutaneous | — | Aug 25, 2021 |
| PALOPEGTERIPARATIDE | Yorvipath subcutaneous | Aug 9, 2024 | |
| NAVEPEGRITIDE | Yuviwel | Feb 27, 2026 |
Ascendis Pharma A/S Trial Locations
Ascendis Pharma A/S clinical trials are running at 110 sites in 19 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (3)
Diseases targeted by Ascendis Pharma A/S's clinical trial and drug development programs
Achondroplasia is the most common form of short-limbed dwarfism, caused by a mutation in the FGFR3 gene that disrupts the conversion of cartilage to bone in the growth plates. This results in dispropo...
Hypoparathyroidism is an endocrine disorder caused by insufficient production of parathyroid hormone (PTH), resulting in chronically low calcium and elevated phosphorus levels in the blood. The most c...
Turner syndrome results from complete or partial absence of an X chromosome in females, causing short stature, gonadal dysgenesis, cardiac and renal abnormalities. Early diagnosis and growth hormone t...
Patient Resources
Organizations and resources related to Ascendis Pharma A/S's rare disease focus areas
Frequently Asked Questions About Ascendis Pharma A/S
Common questions about Ascendis Pharma A/S's rare disease programs, clinical trials, and treatments.